CD52 (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "CD52" in Spanish language version.

Last modified: 13:07:37, 21 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank Spanish rank

66nih.gov

5^th place

66doi.org

2^nd place

33archive.org

6^th place

4^th place

11ox.ac.uk

541^st place

905^th place

11thelancet.com

2,615^th place

2,166^th place

archive.org (Global: 6^th place; Spanish: 4^th place)

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (September 2002). «Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab». Blood 100 (5): 1715-20. PMID 12176892. doi:10.1182/blood.V100.5.1715.h81702001715_1715_1720.
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW (February 2003). «Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation». Blood 101 (4): 1422-9. PMID 12393688. doi:10.1182/blood-2002-04-1093.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). «Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial». Lancet 380 (9856): 1829-39. PMID 23122650. doi:10.1016/S0140-6736(12)61768-1.

doi.org (Global: 2^nd place; Spanish: 2^nd place)

dx.doi.org

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (September 2002). «Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab». Blood 100 (5): 1715-20. PMID 12176892. doi:10.1182/blood.V100.5.1715.h81702001715_1715_1720.
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW (February 2003). «Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation». Blood 101 (4): 1422-9. PMID 12393688. doi:10.1182/blood-2002-04-1093.
Hale G, Waldmann H (2000). «From Laboratory to Clinic : The Story of CAM PA TH-1». Methods Mol. Med. 40: 243-66. ISBN 978-1-59259-076-6. PMID 21337094. doi:10.1385/1-59259-076-4:243.
Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (April 2007). «Expression of CD52 in peripheral T-cell lymphoma». Haematologica 92 (4): 566-7. PMID 17488672. doi:10.3324/haematol.10767.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). «Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial». Lancet 380 (9856): 1829-39. PMID 23122650. doi:10.1016/S0140-6736(12)61768-1.
Cohen, Jeffrey; Coles A; Arnold D (24 de noviembre de 2012). «Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial». The Lancet 380 (9856): 1819-1828. PMID 23122652. doi:10.1016/S0140-6736(12)61769-3. Consultado el 28 de diciembre de 2012.

nih.gov (Global: 5^th place; Spanish: 5^th place)

ncbi.nlm.nih.gov

Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (September 2002). «Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab». Blood 100 (5): 1715-20. PMID 12176892. doi:10.1182/blood.V100.5.1715.h81702001715_1715_1720.
Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW (February 2003). «Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation». Blood 101 (4): 1422-9. PMID 12393688. doi:10.1182/blood-2002-04-1093.
Hale G, Waldmann H (2000). «From Laboratory to Clinic : The Story of CAM PA TH-1». Methods Mol. Med. 40: 243-66. ISBN 978-1-59259-076-6. PMID 21337094. doi:10.1385/1-59259-076-4:243.
Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (April 2007). «Expression of CD52 in peripheral T-cell lymphoma». Haematologica 92 (4): 566-7. PMID 17488672. doi:10.3324/haematol.10767.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). «Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial». Lancet 380 (9856): 1829-39. PMID 23122650. doi:10.1016/S0140-6736(12)61768-1.
Cohen, Jeffrey; Coles A; Arnold D (24 de noviembre de 2012). «Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial». The Lancet 380 (9856): 1819-1828. PMID 23122652. doi:10.1016/S0140-6736(12)61769-3. Consultado el 28 de diciembre de 2012.

ox.ac.uk (Global: 541^st place; Spanish: 905^th place)

users.path.ox.ac.uk

Hale G, Waldmann H (2000). «From Laboratory to Clinic : The Story of CAM PA TH-1». Methods Mol. Med. 40: 243-66. ISBN 978-1-59259-076-6. PMID 21337094. doi:10.1385/1-59259-076-4:243.

thelancet.com (Global: 2,615^th place; Spanish: 2,166^th place)

Cohen, Jeffrey; Coles A; Arnold D (24 de noviembre de 2012). «Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial». The Lancet 380 (9856): 1819-1828. PMID 23122652. doi:10.1016/S0140-6736(12)61769-3. Consultado el 28 de diciembre de 2012.

CD52 (Spanish Wikipedia)

archive.org (Global: 6th place; Spanish: 4th place)

doi.org (Global: 2nd place; Spanish: 2nd place)